Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1934Neoplasms 1387Carcinoma, Non-Small-Cell Lung 1328Prostatic Neoplasms 1072Multiple Myeloma 857Leukemia, Myeloid, Acute 764Neoplasm Metastasis 693Colorectal Neoplasms 679Melanoma 671Lung Neoplasms 666Lymphoma 656Leukemia 592Lymphoma, Non-Hodgkin 588Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 522Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 473Recurrence 466Myelodysplastic Syndromes 422Lymphoma, Follicular 407Head and Neck Neoplasms 402Carcinoma, Renal Cell 377Glioblastoma 376Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 371Hodgkin Disease 352Carcinoma, Hepatocellular 325Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

Melatonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has results × Angelman Syndrome × Clear all
NCT01906866 2024-04-23

Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Neurim Pharmaceuticals Ltd.

Phase 3 Completed
125 enrolled 22 charts

Autism Spectrum Disorder, Sleep Wake Disorders, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔